Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease
Dw. Kitzman et Dj. Wesley, Safety assessment of perflenapent emulsion for echocardiographic contrast enhancement in patients with congestive heart failure or chronic obstructive pulmonary disease, AM HEART J, 139(6), 2000, pp. 1077-1080
Citations number
8
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Background Perflenapent injectable emulsion is a newer echocardiographic co
ntrast agent that provides chamber opacification and improved endocardial b
order delineation. In >1000 patients tested, adverse effects have been mini
mal. However, previous studies have included few patients with congestive h
eart failure (CHF) or severe chronic obstructive pulmonary disease (COPD).
Because of their reduced cardiopulmonary reserve, these patients might be a
t greater risk for adverse events.
Methods and Results The safety of perflenapent emulsion was evaluated in am
bulatory patients with New York Heart Association class III to IV congestiv
e heart failure (CHF) or severe obstructive pulmonary disease (COPD). In 2
separate multicenter, phase II, randomized, double-blind, placebo-controlle
d, single-administration clinical trials, 146 patients in the CHF study and
134 patients in the COPD study received either perflenapent emulsion or sa
line placebo during an echocardiographic examination. Perflenapent emulsion
was well tolerated in patients with CHF or COPD. The adverse event rates w
ith perflenapent emulsion (15%) were similar to those with saline (11%; P =
.43) in the combined groups, and similar findings were seen when analyzed
by CHF or COPD groups separately. All adverse events were rated as mild, re
quired no treatment, resolved spontaneously, and left no sequelae. Changes
from baseline in vital signs, pulse oximetry, electrocardiography, and labo
ratory tests were similar between treatment groups.
Conclusions These data support the safety of perflenapent emulsion for cont
rast echocardiography in stable ambulatory patients with CHF or COPD.